|
|
News Breaks | | | | November 15, 2012 | | 07:36 EDT |  | THLD | Threshold Pharmaceuticals reports updated Phase 2 Results for TH-302
Threshold Pharmaceuticals announced updated results from a Phase 2 study of TH-302, the company's investigational hypoxia-targeted drug, in patients with soft tissue sarcoma, including additional results from patients who were administered TH-302 as single agent maintenance therapy following induction with TH-302 in combination with doxorubicin. The results were reported at the 17th annual meeting of the Connective Tissue Oncology Society, or CTOS, taking place Nov. 14-17, in Prague, Czech Republic. Results for Overall Study Population-- Updated results for the 91 patients in the Phase 2 component of the study include: Median progression free survival, or PFS, of 6.7 months. Median overall survival of 21.5 months. One-year survival of 73%, and two-year survival of 44%. Overall best response of 36%. Results for TH-302 Single Agent Maintenance Therapy Population -- Of 91 patients enrolled in the study, 48, or 53%, continued on TH-302 maintenance therapy. The median number of treatment cycles with TH-302 was 4.0. Median PFS was 3.7 months. Median overall survival was 18.0 months. Overall best response (partial and complete responses, unconfirmed) of 54%; five patients who previously had stable disease prior to maintenance achieved a partial response, and one patient who previously had a partial response achieved a complete response. | |
|
News For THLD From The Last 14 Days Check below for free stories on THLD the last two weeks. |
|
|
| There are no results for THLD |
|
|
|
|
|
|
